In contrast, the risk of severe COVID-19 in humans goes up significantly with age, as does evidence of activin signaling, and is especially prevalent in aged patients with comorbidities; thus the hamster model is perhaps most useful for derisking activin therapy, as opposed to predicting its efficacy. This evidence concerns the gene INHBE and COVID-19.